(Q36802680)

16 August 2017

1 reference

title

Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases (English)

1 reference

16 August 2017

1

Olaf Stüve

1 reference

16 August 2017

Jeffrey L Bennett

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6494150&resulttype=core&format=json

14 May 2020

Olaf Stüve

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6494150&resulttype=core&format=json

14 May 2020

language of work or name

1 reference

1 January 2007

1 reference

17461891

CNS Neuroscience & Therapeutics

16 August 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6494150&resulttype=core&format=json

14 May 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6494150&resulttype=core&format=json

14 May 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6494150&resulttype=core&format=json

14 May 2020

page(s)

79-95

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6494150&resulttype=core&format=json

Predicting the kinetics of peptide-antibody interactions using a multivariate experimental design of sequence and chemical space

14 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00003.X

Natalizumab and progressive multifocal leukoencephalopathy: migrating towards safe adhesion molecule therapy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00003.X

Progressive multifocal leukoencephalopathy: lessons from AIDS and natalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00003.X

Integrin avidity regulation: are changes in affinity and conformation underemphasized?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00003.X

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00003.X

Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00003.X

Quantification of MRI lesion load in multiple sclerosis: a comparison of three computer-assisted techniques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00003.X

Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00003.X

T-cell integrins: more than just sticking points

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00003.X

Suppression of experimental allergic encephalomyelitis in Lewis rats after elimination of macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00003.X

Integrins: bidirectional, allosteric signaling machines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00003.X

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00003.X

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00003.X

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00003.X

The primacy of affinity over clustering in regulation of adhesiveness of the integrin {alpha}L{beta}2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00003.X

Intracellular signalling controlling integrin activation in lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00003.X

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00003.X

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00003.X

Rapid leukocyte integrin activation by chemokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00003.X

Force probe measurements of antibody-antigen interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00003.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00003.X

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00003.X

Immune cell migration in inflammation: present and future therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00003.X

A controlled trial of natalizumab for relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00003.X

Bimolecular complex between rolling and firm adhesion receptors required for cell arrest; CD44 association with VLA-4 in T cell extravasation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00003.X

Ligation of VLA-4 on T cells stimulates tyrosine phosphorylation of a 105-kD protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00003.X

Suppression of acute experimental allergic encephalomyelitis with a small molecule inhibitor of alpha4 integrin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00003.X

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00003.X

New and emerging treatment options for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00003.X

ENCEPHALOMYELITIS ACCOMPANIED BY MYELIN DESTRUCTION EXPERIMENTALLY PRODUCED IN MONKEYS

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00003.X

OBSERVATIONS ON ATTEMPTS TO PRODUCE ACUTE DISSEMINATED ENCEPHALOMYELITIS IN MONKEYS

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00003.X

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00003.X

Roles of adhesion molecules in T-cell recognition: fundamental similarities between four integrins on resting human T cells (LFA-1, VLA-4, VLA-5, VLA-6) in expression, binding, and costimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00003.X

CXCR2- and E-selectin-induced neutrophil arrest during inflammation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00003.X

Immune surveillance in multiple sclerosis patients treated with natalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00003.X

Experimental autoimmune encephalomyelitis in rodents as a model for human demyelinating disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00003.X

Differential effects of treatment with a small-molecule VLA-4 antagonist before and after onset of relapsing EAE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00003.X

Alpha4-integrin-VCAM-1 binding mediates G protein-independent capture of encephalitogenic T cell blasts to CNS white matter microvessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00003.X

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00003.X

An open-label safety and drug interaction study of natalizumab (Antegren) in combination with interferon-beta (Avonex) in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00003.X

Antibody-antigen interactions: new structures and new conformational changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00003.X

Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00003.X

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00003.X

The T lymphocyte in experimental allergic encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00003.X

β7 integrins contribute to demyelinating disease of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00003.X

Natalizumab effects on immune cell responses in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00003.X

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00003.X

Modulation of VLA-4 and L-selectin expression on normal CD34+ cells during mobilization with G-CSF

21 January 2018

1 reference

12 December 2020

A safety and pharmacokinetic study of intravenous natalizumab in patients with MS

1 reference

12 December 2020

The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group

1 reference

12 December 2020

Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group

1 reference

12 December 2020

Leukocyte arrest during cytokine-dependent inflammation in vivo

1 reference

12 December 2020

Integrin cytoplasmic domain-binding proteins

1 reference

12 December 2020

Discordant effects of anti-VLA-4 treatment before and after onset of relapsing experimental autoimmune encephalomyelitis.

1 reference

12 December 2020

Prolonged reversal of chronic experimental allergic encephalomyelitis using a small molecule inhibitor of alpha4 integrin

1 reference

12 December 2020

Engineering antibodies for therapy

1 reference

12 December 2020

Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects

1 reference

12 December 2020

Rolling of Th1 cells via P-selectin glycoprotein ligand-1 stimulates LFA-1-mediated cell binding to ICAM-1.

1 reference

12 December 2020

Lymphocyte arrest requires instantaneous induction of an extended LFA-1 conformation mediated by endothelium-bound chemokines

1 reference

12 December 2020

Spontaneous remyelination following prolonged inhibition of alpha4 integrin in chronic EAE

1 reference

12 December 2020

1 reference

12 December 2020

Selective treatment of multiple sclerosis

1 reference

12 December 2020

Fibronectin promotes proliferation of naive and memory T cells by signaling through both the VLA-4 and VLA-5 integrin molecules

1 reference

12 December 2020

Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis

1 reference

12 December 2020

Costimulation of proliferative responses of resting CD4+ T cells by the interaction of VLA-4 and VLA-5 with fibronectin or VLA-6 with laminin

1 reference

12 December 2020

Role of the VLA-4 molecule in T cell costimulation. Identification of the tyrosine phosphorylation pattern induced by the ligation of VLA-4.

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

Humanization of a mouse antibody against human alpha-4 integrin: a potential therapeutic for the treatment of multiple sclerosis

1 reference

12 December 2020

Efflux of CD34+ cells from bone marrow to peripheral blood is selective in steady-state hematopoiesis and during G-CSF administration

1 reference

12 December 2020

Rescue from apoptosis in early (CD34-selected) versus late (non-CD34-selected) human hematopoietic cells by very late antigen 4- and vascular cell adhesion molecule (VCAM) 1-dependent adhesion to bone marrow stromal cells

1 reference

12 December 2020

Different adhesive characteristics and VLA-4 expression of CD34(+) progenitors in G0/G1 versus S+G2/M phases of the cell cycle.

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

10.1111/J.1527-3458.2007.00003.X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6494150&resulttype=core&format=json

14 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6494150&resulttype=core&format=json

14 May 2020

17461891

1 reference